Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

SARAH K TASIAN

Allopathic & Osteopathic Physicians Pediatrics Pediatric Hematology-Oncology

NPI
1013027077
CMS profile
1132369
Location
PHILADELPHIA, PA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$125.18

1 record · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $125.18 1

By paying entity

PY2019 · entire year · sorted by reported total

Paying entityAmountRecords
JAZZ PHARMACEUTICALS INC. $125.18 1

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

SARAH K TASIAN

NPI 1013027077 · CMS profile ID 1132369

Allopathic & Osteopathic Physicians / Pediatrics / Pediatric Hematology-Oncology

PHILADELPHIA, PA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1013027077?year=2019&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
SARAH K TASIAN, NPI 1013027077, CMS profile ID 1132369. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1013027077?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). SARAH K TASIAN, NPI 1013027077, CMS profile ID 1132369. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1013027077?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
SARAH K TASIAN, NPI 1013027077, CMS profile ID 1132369, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1013027077?year=2019&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

1 matching record · $125.18 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 1 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–1 of 1.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
JAZZ PHARMACEUTICALS INC. $125.1809/11/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 684177597 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $125.18 1
PY2022 $12,692.29 5
PY2023 $16,204.01 8
PY2024 $40,847.07 25
PY2025 $19,866.78 23

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2022, 2023, 2024, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2022 , PY2023 , PY2024 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $376,661.72 26
PY2024 Principal investigator $492,636.09 23
PY2023 Principal investigator $24,589.12 11
PY2022 Principal investigator $39,173.75 6
PY2021 Principal investigator $433.67 12
PY2020 Principal investigator $178.59 4
PY2019 Recipient $93.48 2
PY2019 Principal investigator $326.23 7

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

26 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Syndax Pharmaceuticals, Inc. $16,240.50 12/09/2025 Covered Recipient Teaching Hospital
THE CHILDRENS HOSPITAL OF PHILADELP
EXPANDED ACCESS PROGRAM FORSNDX-5613IN PATIENTS WITH RELAPSED/REFRACTORY ACUTE LEUKEMIAS WITH GENETIC ALTERATIONS ASSOCIATED WITH HOXA OVEREXPRESSION No dispute reported 06/30/2026 1249049738
Principal investigator 1 SANOFI US SERVICES INC. $1,675.00 12/08/2025 Covered Recipient Teaching Hospital
The Childrens Hospital Of Philadelp
An Open-label, First-in-human, Dose-escalation Study of SAR443579 Administered as Single Agent by Intravenous Infusion in Patients With Relapsed or Refractory Acute Myeloid Leukemia (R/R AML), B-cell Acute Lymphoblastic Leukemia (B-ALL) or High Risk-myelodysplasia (HR-MDS) No dispute reported 06/30/2026 1226129755
Principal investigator 1 Novartis Pharmaceuticals Corporation $70.00 12/01/2025 Covered Recipient Teaching Hospital
The Childrens Hospital Of Philadelp
A Multi-center, Open-label Study to Determine the Dose and Safety of Oral Asciminib in Pediatric Patients With Philadelphia Chromosome Positive Chronic Myeloid Leukemia in Chronic Phase (Ph+ CML-CP), Previously Treated With One or More Tyrosine Kinase Inh No dispute reported 06/30/2026 1190297481
Principal investigator 1 Syndax Pharmaceuticals, Inc. $1,666.00 11/05/2025 Covered Recipient Teaching Hospital
THE CHILDRENS HOSPITAL OF PHILADELP
EXPANDED ACCESS PROGRAM FORSNDX-5613IN PATIENTS WITH RELAPSED/REFRACTORY ACUTE LEUKEMIAS WITH GENETIC ALTERATIONS ASSOCIATED WITH HOXA OVEREXPRESSION No dispute reported 06/30/2026 1249049736
Principal investigator 1 SANOFI US SERVICES INC. $6,075.00 09/22/2025 Covered Recipient Teaching Hospital
The Childrens Hospital Of Philadelp
An Open-label, First-in-human, Dose-escalation Study of SAR443579 Administered as Single Agent by Intravenous Infusion in Patients With Relapsed or Refractory Acute Myeloid Leukemia (R/R AML), B-cell Acute Lymphoblastic Leukemia (B-ALL) or High Risk-myelodysplasia (HR-MDS) No dispute reported 06/30/2026 1226129736
Principal investigator 1 Astellas Pharma Global Development $7,615.00 09/18/2025 Covered Recipient Teaching Hospital
The Childrens Hospital Of Philadelp
A Phase 1/2, Multicenter, Open-Label, Single Arm, Dose Escalation and Expansion Study of Gilteritinib (ASP2215) Combined With Chemotherapy in Children, Adolescents and Young Adults With FMS-like Tyrosine Kinase 3 (FLT3)/Internal Tandem Duplication (ITD) Positive Relapsed or Refractory Acute Myeloid Leukemia (AML) No dispute reported 06/30/2026 1234181060
Principal investigator 1 Astellas Pharma Global Development $5,862.50 09/18/2025 Covered Recipient Teaching Hospital
The Childrens Hospital Of Philadelp
A Phase 1/2, Multicenter, Open-Label, Single Arm, Dose Escalation and Expansion Study of Gilteritinib (ASP2215) Combined With Chemotherapy in Children, Adolescents and Young Adults With FMS-like Tyrosine Kinase 3 (FLT3)/Internal Tandem Duplication (ITD) Positive Relapsed or Refractory Acute Myeloid Leukemia (AML) No dispute reported 06/30/2026 1234181062
Principal investigator 1 SANOFI US SERVICES INC. $1,675.00 08/11/2025 Covered Recipient Teaching Hospital
The Childrens Hospital Of Philadelp
An Open-label, First-in-human, Dose-escalation Study of SAR443579 Administered as Single Agent by Intravenous Infusion in Patients With Relapsed or Refractory Acute Myeloid Leukemia (R/R AML), B-cell Acute Lymphoblastic Leukemia (B-ALL) or High Risk-myelodysplasia (HR-MDS) No dispute reported 06/30/2026 1226129714
Principal investigator 1 ABBVIE INC. $310.28 07/14/2025 Non-covered Recipient Entity
ACM MEDICAL LABORATORY INC
B19-061 Ph 3 Pediatric Study of venetoclax and chemotherapy No dispute reported 06/30/2026 1202498126
Principal investigator 1 SANOFI US SERVICES INC. $1,675.00 06/23/2025 Covered Recipient Teaching Hospital
The Childrens Hospital Of Philadelp
An Open-label, First-in-human, Dose-escalation Study of SAR443579 Administered as Single Agent by Intravenous Infusion in Patients With Relapsed or Refractory Acute Myeloid Leukemia (R/R AML), B-cell Acute Lymphoblastic Leukemia (B-ALL) or High Risk-myelodysplasia (HR-MDS) No dispute reported 06/30/2026 1226129706
Principal investigator 1 ABBVIE INC. $1,687.50 06/17/2025 Covered Recipient Teaching Hospital
THE CHILDRENS HOSPITAL OF PHILADELP
B19-061 Ph 3 Pediatric Study of venetoclax and chemotherapy No dispute reported 06/30/2026 1202422775
Principal investigator 1 SANOFI US SERVICES INC. $17,110.80 05/27/2025 Covered Recipient Teaching Hospital
The Childrens Hospital Of Philadelp
An Open-label, First-in-human, Dose-escalation Study of SAR443579 Administered as Single Agent by Intravenous Infusion in Patients With Relapsed or Refractory Acute Myeloid Leukemia (R/R AML), B-cell Acute Lymphoblastic Leukemia (B-ALL) or High Risk-myelodysplasia (HR-MDS) No dispute reported 06/30/2026 1226129698
Principal investigator 1 Astellas Pharma Global Development $1,540.00 05/08/2025 Covered Recipient Teaching Hospital
The Childrens Hospital Of Philadelp
A Phase 1/2, Multicenter, Open-Label, Single Arm, Dose Escalation and Expansion Study of Gilteritinib (ASP2215) Combined With Chemotherapy in Children, Adolescents and Young Adults With FMS-like Tyrosine Kinase 3 (FLT3)/Internal Tandem Duplication (ITD) Positive Relapsed or Refractory Acute Myeloid Leukemia (AML) No dispute reported 06/30/2026 1234181058
Principal investigator 1 Syndax Pharmaceuticals, Inc. $15,354.50 05/05/2025 Covered Recipient Teaching Hospital
THE CHILDRENS HOSPITAL OF PHILADELP
EXPANDED ACCESS PROGRAM FORSNDX-5613IN PATIENTS WITH RELAPSED/REFRACTORY ACUTE LEUKEMIAS WITH GENETIC ALTERATIONS ASSOCIATED WITH HOXA OVEREXPRESSION No dispute reported 06/30/2026 1249049734
Principal investigator 1 Incyte Corporation $14,313.00 04/16/2025 Covered Recipient Teaching Hospital
The Childrens Hospital Of Philadelp
A Phase 2 Study of the JAK1, JAK2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High Risk CRLF2 Rearranged and or JAK Pathway Mutant Acute Lymphoblastic Leukemia No dispute reported 06/30/2026 1240489255
Principal investigator 1 SANOFI US SERVICES INC. $5,400.00 04/14/2025 Covered Recipient Teaching Hospital
The Childrens Hospital Of Philadelp
An Open-label, First-in-human, Dose-escalation Study of SAR443579 Administered as Single Agent by Intravenous Infusion in Patients With Relapsed or Refractory Acute Myeloid Leukemia (R/R AML), B-cell Acute Lymphoblastic Leukemia (B-ALL) or High Risk-myelodysplasia (HR-MDS) No dispute reported 06/30/2026 1226129689
Principal investigator 1 SANOFI US SERVICES INC. $61,033.10 04/07/2025 Covered Recipient Teaching Hospital
The Childrens Hospital Of Philadelp
An Open-label, First-in-human, Dose-escalation Study of SAR443579 Administered as Single Agent by Intravenous Infusion in Patients With Relapsed or Refractory Acute Myeloid Leukemia (R/R AML), B-cell Acute Lymphoblastic Leukemia (B-ALL) or High Risk-myelodysplasia (HR-MDS) No dispute reported 06/30/2026 1226129685
Principal investigator 1 SANOFI US SERVICES INC. $7,189.20 03/24/2025 Covered Recipient Teaching Hospital
The Childrens Hospital Of Philadelp
An Open-label, First-in-human, Dose-escalation Study of SAR443579 Administered as Single Agent by Intravenous Infusion in Patients With Relapsed or Refractory Acute Myeloid Leukemia (R/R AML), B-cell Acute Lymphoblastic Leukemia (B-ALL) or High Risk-myelodysplasia (HR-MDS) No dispute reported 06/30/2026 1226129682
Principal investigator 1 Novartis Pharmaceuticals Corporation $5,943.75 03/06/2025 Non-covered Recipient Entity
CHILDRENS HOSPITAL OF PHILADELPHIA
A Multi-center, Open-label Study to Determine the Dose and Safety of Oral Asciminib in Pediatric Patients With Philadelphia Chromosome Positive Chronic Myeloid Leukemia in Chronic Phase (Ph+ CML-CP), Previously Treated With One or More Tyrosine Kinase Inh No dispute reported 06/30/2026 1190298924
Principal investigator 1 SANOFI US SERVICES INC. $810.00 02/24/2025 Covered Recipient Teaching Hospital
The Childrens Hospital Of Philadelp
An Open-label, First-in-human, Dose-escalation Study of SAR443579 Administered as Single Agent by Intravenous Infusion in Patients With Relapsed or Refractory Acute Myeloid Leukemia (R/R AML), B-cell Acute Lymphoblastic Leukemia (B-ALL) or High Risk-myelodysplasia (HR-MDS) No dispute reported 06/30/2026 1226129669
Principal investigator 1 SANOFI US SERVICES INC. $55,702.80 02/24/2025 Covered Recipient Teaching Hospital
The Childrens Hospital Of Philadelp
An Open-label, First-in-human, Dose-escalation Study of SAR443579 Administered as Single Agent by Intravenous Infusion in Patients With Relapsed or Refractory Acute Myeloid Leukemia (R/R AML), B-cell Acute Lymphoblastic Leukemia (B-ALL) or High Risk-myelodysplasia (HR-MDS) No dispute reported 06/30/2026 1226129674
Principal investigator 1 SANOFI US SERVICES INC. $62,464.50 02/24/2025 Covered Recipient Teaching Hospital
The Childrens Hospital Of Philadelp
An Open-label, First-in-human, Dose-escalation Study of SAR443579 Administered as Single Agent by Intravenous Infusion in Patients With Relapsed or Refractory Acute Myeloid Leukemia (R/R AML), B-cell Acute Lymphoblastic Leukemia (B-ALL) or High Risk-myelodysplasia (HR-MDS) No dispute reported 06/30/2026 1226129678
Principal investigator 1 SANOFI US SERVICES INC. $71,816.40 02/10/2025 Covered Recipient Teaching Hospital
The Childrens Hospital Of Philadelp
An Open-label, First-in-human, Dose-escalation Study of SAR443579 Administered as Single Agent by Intravenous Infusion in Patients With Relapsed or Refractory Acute Myeloid Leukemia (R/R AML), B-cell Acute Lymphoblastic Leukemia (B-ALL) or High Risk-myelodysplasia (HR-MDS) No dispute reported 06/30/2026 1226129665
Principal investigator 1 SANOFI US SERVICES INC. $6,591.75 02/04/2025 Covered Recipient Teaching Hospital
The Childrens Hospital Of Philadelp
An Open-label, First-in-human, Dose-escalation Study of SAR443579 Administered as Single Agent by Intravenous Infusion in Patients With Relapsed or Refractory Acute Myeloid Leukemia (R/R AML), B-cell Acute Lymphoblastic Leukemia (B-ALL) or High Risk-myelodysplasia (HR-MDS) No dispute reported 06/30/2026 1226129662
Principal investigator 1 Syndax Pharmaceuticals, Inc. $3,875.00 01/29/2025 Covered Recipient Teaching Hospital
THE CHILDRENS HOSPITAL OF PHILADELP
AUGMENT-102: A PHASE 1, OPEN-LABEL, DOSE-ESCALATION STUDY TO EVALUATE SAFETY, TOLERABILITY AND PRELIMINARY ANTI-LEUKEMIC ACTIVITY OF SNDX-5613 IN COMBINATION WITH CHEMOTHERAPY IN PATIENTS WITH RELAPSED/REFRACTORY LEUKEMIAS HARBORING ALTERATIONS IN KMT2A/MLL, NUCLEOPHOSMIN 1 (NPM1), AND NUCLEOPORIN 98 (NUP98) GENES No dispute reported 06/30/2026 1249049732
Principal investigator 1 Novartis Pharmaceuticals Corporation $2,965.14 01/01/2025 Covered Recipient Teaching Hospital
The Childrens Hospital Of Philadelp
A Multi-center, Open-label Study to Determine the Dose and Safety of Oral Asciminib in Pediatric Patients With Philadelphia Chromosome Positive Chronic Myeloid Leukemia in Chronic Phase (Ph+ CML-CP), Previously Treated With One or More Tyrosine Kinase Inh No dispute reported 06/30/2026 1190294748